Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Simultaneously complete but not partial taste and smell losses were associated with SARS-CoV-2 infection

Dunyaporn Trachootham\textsuperscript{a,}*\textsuperscript{a}, Supeda Thongyen\textsuperscript{b}, Aroonwan Lam-Ubol\textsuperscript{c}, Nattida Chotechuang\textsuperscript{d}, Wannarat Pongpirul\textsuperscript{b}, Wisit Prasithsirikul\textsuperscript{b}

\textsuperscript{a} Institute of Nutrition, Mahidol University, Nakhon Pathom, Thailand
\textsuperscript{b} Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Nonthaburi, Thailand
\textsuperscript{c} Department of Oral Surgery and Oral Medicine, Faculty of Dentistry, Srinakharinwirot University, Bangkok, Thailand
\textsuperscript{d} Department of Food Technology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand

\textbf{A R T I C L E   I N F O}

\textbf{Article history:}
Received 10 January 2021
Received in revised form 26 March 2021
Accepted 28 March 2021

\textbf{Keywords:}
COVID-19
Taste
Smell
Appetite
Case–control study
Thai

\textbf{A B S T R A C T}

\textbf{Objectives:} The aim of this study was to investigate the association between taste and smell losses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and to elucidate whether taste preference influences such taste loss.

\textbf{Methods:} A matched case–control study was conducted in 366 Thai participants, including 122 who were confirmed SARS-CoV-2-positive by RT-PCR (case group) and 244 who were SARS-CoV-2-negative (control group). Taste, smell, and appetite changes were assessed by self-reported visual analog scale. Preference for sweet, salty, umami, sour, bitter, and spicy were judged using the validated TASTE-26 questionnaire.

\textbf{Results:} Partial taste and smell losses were observed in both groups, while complete losses (ageusia and anosmia) were detected only in the case group. Moreover, only ageusia and anosmia were associated with SARS-CoV-2 positivity ($P<0.001$, odds ratio of 14.5 and 27.5, respectively). Taste, smell, and appetite scores were more severely reduced in the case group ($P<0.0001$). Multivariate analysis showed that anosmia and ageusia were the best predictors of SARS-CoV-2 positivity, followed by appetite loss and fever. Simultaneous losses of taste and smell but not taste preferences were associated with SARS-CoV-2 positivity ($P<0.01$, odds ratio 2.28).

\textbf{Conclusions:} Complete, but not partial, losses of taste and smell were the best predictors of SARS-CoV-2 infection. During the current COVID-19 pandemic, healthy persons with sudden simultaneous complete loss of taste and smell should be screened for COVID-19.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

\textbf{Introduction}

Coronavirus disease 2019 (COVID-19) is a pandemic respiratory infectious disease, with 110.7 million cases leading to over 2.4 million deaths reported globally on 23 February, 2021 (\textit{World Health Organization, 2020a}). COVID-19 is caused by a novel pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (\textit{World Health Organization, 2020b}). Early detection could help reduce the morbidity and mortality rates (Hashmi and Asif, 2020). Common symptoms of COVID-19 include a body temperature >37.5 °C and a dry cough in mild cases, fever, cough, abdominal discomfort, and abnormal blood biomarkers in moderate cases, and difficulty breathing and dyspnea in severe cases (Guan et al., 2020). Unfortunately, these symptoms are comparatively similar to those of other respiratory infectious diseases such as influenza (Hashmi and Asif, 2020). Therefore, there is a need to identify pathognomonic features of COVID-19.

Besides respiratory symptoms, alterations in gustatory and olfactory function are commonly found in COVID-19. A systemic review and meta-analysis reported that the overall prevalence of alterations in taste and smell senses among COVID-19 patients was 47% (Borsetto et al., 2020). Some patients have had reduced taste and smell senses (hypogeusia and hyposmia, respectively), while others have had complete losses of taste and smell (ageusia and anosmia) (Vaira et al., 2020). Interestingly, isolated sudden onset

\textsuperscript{*} Corresponding author at: Dunyaporn Trachootham, Institute of Nutrition, Mahidol University, 999 Phutthamonthon Sai 4 Road, Salaya, Nakhon Pathom, 73170, Thailand.
\textit{E-mail addresses:} dunyaporn.tra@mahidol.ac.th, dunyaporn.tra@mahidol.edu (D. Trachootham).

\url{https://doi.org/10.1016/j.ijid.2021.03.083}
1201-9712© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
anosmia (ISOA) occurring separately from nasal obstruction or rhinitis has been variably reported in 22–88% of SARS-CoV-2–infected individuals (Gane et al., 2020; Bagheri et al., 2020). The underlying mechanisms of the taste and smell losses in COVID-19 cases remain unclear. Existing evidence suggests that SARS-CoV-2 could bind to angiotensin converting enzyme 2 (ACE2), which is highly expressed in nasal mucosa (Sungnak et al., 2020). Since the anosmia in COVID-19 cases may occur without nasal obstruction, neurotoxicity of SARS-CoV-2 to olfactory and gustatory neurons has been proposed as a potential mechanism of taste and smell losses (Jafari et al., 2020).

Smell alteration can be caused by upper respiratory infections, allergic rhinitis, sinusitis, nasal polyps, head trauma, neurological disorders such as Parkinson’s disease, Alzheimer’s disease, psychiatric disorders such as major depression, medications, toxins, vitamin B12 deficiency, and autoimmune diseases such as systemic lupus erythematosus (Malaty and Malaty, 2020). Taste alteration can be caused by aging, zinc deficiency, viral infection, neurological diseases, radiation therapy, chronic alcohol consumption, smoking, nerve or brain trauma, and medications causing hyposalivation (Risso et al., 2020). Previous studies on taste and smell alterations in COVID-19 patients have mostly been of cross-sectional design. Thus, the observed association could be confounded by other factors. Currently, it is still unclear whether SARS-CoV-2 infection has a causal association with hypogeusia, ageusia, hyposmia, and anosmia (Tanasa et al., 2020).

People with a stronger preference for a certain taste often have a higher recognition threshold for that taste, i.e. a higher concentration of the taste substance is required to recognize the taste (Chamoun et al., 2019). A previous study in cancer patients receiving radiation therapy showed that patients with higher taste thresholds were more susceptible to taste loss than those with lower taste thresholds (Vittayakasemsont, 2016). Thus, it was speculated that people with a stronger taste preference may be more sensitive to taste loss than others. However, it is unknown whether taste preference is associated with taste alteration in COVID-19 cases.

The aim of this PCR-confirmed case–control study was to investigate the association between taste and smell losses and SARS-CoV-2 infection, and to elucidate whether taste preference affects COVID-19–related taste loss.

Materials and methods

Ethical aspects and setting

This study was conducted at the Bamrasnaradura Infectious Diseases Institute, Department of Health, Ministry of Health, Nonthaburi, Thailand. The study protocol was approved on April 30, 2020 by the Ethics Committee of Bamrasnaradura Infectious Diseases Institute (COA. No. IRB/BIDI S023’h/63_ExPD). Written informed consent was obtained from each participant prior to data collection.

Study design and study period

This case–control study was conducted during April to June 2020, which was the period of highest COVID-19 prevalence in Thailand. The case group included persons who tested positive for SARS-CoV-2 by real-time PCR (RT-PCR). The control group comprised persons who tested negative for SARS-CoV-2 by RT-PCR. It is worth noting that during the study period, the SARS-CoV-2 infection in Thailand was mainly the strain found originally in Wuhan, Hubei, China (Manmana et al., 2020).

Participants

Inclusion criteria for participants were Thai nationality, age ≥18 years, able to communicate in Thai, comfortable answering the questionnaire, and had been tested by RT-PCR for SARS-CoV-2. Exclusion criteria included any inability to provide reliable communication; e.g. critical patients on a respirator, unconscious patients, those in a coma, and patients with psychiatric disorders or dementia. All participants signed a written informed consent agreement before data collection. Their identities were protected, in accordance with the Declaration of Helsinki. The case and control groups were matched for age, sex, body mass index (BMI), and systemic disease, with an allocation ratio of two controls per one case.

Sample size and power

The effect size was calculated based on two studies. The incidence of taste and smell changes was 22% in COVID-19 cases in China and Korea (Mao et al., 2020), while alterations in taste and smell were found in 9% of the general population in Korea (Kang et al., 2020). A two-tailed significance level of 0.05 and 90% power were used to calculate the sample size for Fisher’s exact test using the program G-Power version 3.1. Since positivity for SARS-CoV-2 was found in 30% of persons receiving the RT-PCR test at Bamrasnaradura Infectious Diseases Institute, the allocation ratio N2/N1 of 2/1 was applied. The calculation yielded a sample size of 366, including 122 persons for the case group and 244 persons for the control group.

Study procedures

Participants were recruited from the Emerging Infectious Disease Clinic of Bamrasnaradura Infectious Diseases Institute, the central hospital with the highest number of COVID-19 cases in Thailand at that time. The reason for undergoing RT-PCR testing for SARS-CoV-2 was either having respiratory symptoms or having a history of contact with an infected person. All participants were screened by a physician according to the inclusion and exclusion criteria. Then, an epidemiologist who had no duties in patient treatment explained the risks and benefits of the study. All participants voluntarily signed informed consent. Participants completed the questionnaire by themselves during the period they were waiting to be tested for SARS-CoV-2 by RT-PCR method. This timing of data collection could reduce subjective bias, since the participants did not know yet whether they had or did not have the infection. Once the test results were returned, participants with positivity for SARS-CoV-2 were assigned to the case group, while those with a negative result were assigned to the control group.

Outcome assessment

The questionnaire included general information, systemic diseases, medication, history of other respiratory diseases, symptoms, and history of contact with COVID-19 cases. The perception of taste and smell was rated using visual analog scales from 0 (no taste/no smell sense) to 10 (full sense of taste/smell). Ageusia/anosmia were defined as having a taste/smell score of 0, after being suspected of having a SARS-CoV-2 infection. Hypogeusia/hyposmia were defined as having a reduction in taste/smell scores, after being suspected of having a SARS-CoV-2 infection. Preferences for sweet, sour, salty, bitter, umami, fatty, and spicy were studied using TASTE-26, a validated questionnaire (Vittayakasemsont et al., 2019). Each participant answered 21 multiple choice questions to describe their dietary preferences during the past 5 years. Each question was answered on a three-point scale.

D. Trachootham, S. Thongyen, A. Lam-Ubol et al. International Journal of Infectious Diseases 106 (2021) 329–337
(0–2 points). For example, “How many glasses of sweetened beverages (e.g., soft drinks, coffee, tea, sweetened herbal drink) do you usually drink daily?” is an example of the question for sweet preference. The answer choices for this questions were ≤ 1 glass/day, 2 glasses per day, ≥ 3 glasses/day. Three questions were included for the evaluation of each taste preference and the sum of the scores was used to categorize the participant into a strong (score 4–6), moderate (score 2–3), or mild (score 0–1) lover of each taste.

**Statistical analyses**

Baseline characteristics of the participants in the case and control groups were compared using the Mann–Whitney test for numerical data or the Chi-square test for categorical data. Associations between each variable and SARS-CoV-2 infection were tested statistically by odds ratio (OR), Fisher’s exact test, or Chi-square test. For the multivariate analysis, dummy codes for the outcome variable SARS-CoV-2 infection were defined as 0 = negative, 1 = positive; dummy codes for symptoms were defined as 0 = without the symptom, 1 = with the symptom. Associations between multiple variables and SARS-CoV-2 infection were analyzed using multiple linear regression. Comparisons of taste/smell scores between the case and control groups were performed using the Mann–Whitney test. The correlation between taste preferences (ordinal scale) and the change in taste score (delta between before and after scores; numerical scale) was analyzed by Spearman rank correlation analysis. Graphing and statistical analyses were performed using GraphPad Prism version 9.0.0. Power and sample size calculations were performed using G-power version 3.1. Values of $P < 0.05$ were considered statistically significant.

**Results**

**Characteristics of the study participants**

Table 1 shows the baseline characteristics of the participants in the case and control groups. There was no significant difference in age, sex, BMI, or systemic diseases between the groups.

**Having respiratory symptoms versus contact with an infected person**

Participants in this study included those either having respiratory symptoms or having been in contact with an infected person. Surprisingly, as shown in Figure 1a, the control group (SARS-CoV-2-negative) had a higher percentage of participants with symptoms than the case group. Thus, contact with infected persons was more associated with SARS-CoV-2 positivity than having respiratory symptoms (odds ratio (OR) 2.29, 95% confidence interval (CI) 1.199–4.465, $P < 0.05$).

**Change in taste sense**

Hypogeusia and ageusia were found in 25.4% and 5.7% of the case group participants and 37.3% and 0% of the control group participants, respectively (Table 2). Ageusia but not hypogeusia was associated with SARS-CoV-2 positivity with an OR of 14.5 (95% confidence interval (CI) 5.74–39.3).

### Table 1

**Characteristics of the study participants**

| Characteristics                  | Case group (n = 122) | Control group (n = 244) | P-value |
|----------------------------------|----------------------|-------------------------|---------|
| Sex                              |                       |                         |         |
| Female                           | 64                   | 136                     | 0.55c   |
| Male                             | 58                   | 108                     |         |
| BMI category†                   |                       |                         |         |
| Obese II                        | 13                   | 28                      | 0.50b   |
| Obese I                         | 24                   | 51                      |         |
| Overweight                      | 22                   | 36                      |         |
| Normal weight                    | 52                   | 117                     |         |
| Underweight                     | 11                   | 12                      |         |
| Systemic diseases               |                       |                         |         |
| None                             | 100                  | 182                     | 0.44b   |
| Allergy, asthma, sinusitis      | 19                   | 52                      |         |
| Others§                         | 3                    | 10                      |         |
| Recent diseases in the past 2 weeks |                   |                         |         |
| None                             | 119                  | 225                     | 0.19b   |
| Streptococcal pharyngitis        | 0                    | 7                       |         |
| Influenza/cold                   | 3                    | 6                       |         |
| Tonsillitis                      | 0                    | 2                       |         |
| Allergy, asthma                  | 0                    | 3                       |         |
| Medical treatment               |                       |                         | 0.08b   |
| None                             | 109                  | 210                     |         |
| Medications§                     | 6                    | 26                      |         |
| Surgery§                        | 7                    | 7                       |         |

| Range   | Mean ± SD | Range   | Mean ± SD |
|---------|-----------|---------|-----------|
| Age (years) | 20–83 | 39.3 ± 15.12 | 18–90 | 38.1 ± 13.6 | 0.78c |
| BMI (kg/m²) | 14.8–44.08 | 23.3 ± 4.7 | 16.4–45.6 | 23.8 ± 4.8 | 0.54d |

Number, number of participants; %, percentage of the total participants; BMI, body mass index; SD, standard deviation.

a Fisher’s exact test.

b Chi-square test.

c Mann–Whitney test.

d Underweight, BMI < 18 kg/m²; normal weight, 18–22.9 kg/m²; overweight, 23–24.9 kg/m²; obese I, 25–29.9 kg/m²; obese II, BMI ≥ 30 kg/m².

§ Case group: menopause (n = 2), neurological disorders (n = 1). Control group: menopause (n = 6), thyroid diseases (n = 3), nasopharyngeal cancer (n = 1).

§ Case group: antihistamines (n = 4), antihypertensives (n = 2). Control group: antihistamines (n = 21), sleeping pills (n = 2), pain killers (n = 2), antibiotics (n = 1).

§ Case group: rhinoplasty (n = 3), tonsillectomy (n = 2), sinus surgery (n = 1), thyroid surgery (n = 1). Control group: rhinoplasty (n = 4), tonsillectomy (n = 2), brain surgery (n = 1).
Furthermore, the infected group had a significantly more severe reduction in taste score ($-4.6 \pm 3.19$) when compared to the control group ($-2.8 \pm 2.66$) ($P < 0.0001$) (Figure 1c). Interestingly, on-and-off taste sense was more frequent in the case group (35%) than in the control group (20%) ($P < 0.0001$) (Figure 2a).

### Table 2

|                     | Case group ($n = 122$) | Control group ($n = 244$) | $P$-value$^a$ | OR     |
|---------------------|------------------------|---------------------------|---------------|--------|
| Complete loss of taste sense (ageusia) | 7                      | 0                         | 0.002         | 14.5$^b$ |
| Reduced taste sense (hypogeusia)       | 31                     | 91                        | 0.06          | 0.62   |
| No changes             | 84                     | 153                       |               |        |

Number, number of participants; %, percentage of the total participants; OR, odds ratio.

$^a$ $P$-value derived from Fisher’s exact test.

$^b$ 95% confidence interval = 2.157–161.9.

---

**Change in smell sense**

Hyposmia and anosmia were found in 21.3% and 10.7% of the case group participants and in 32.8% and 0% of the control group participants, respectively (Table 3). Anosmia but not hyposmia was associated with SARS-CoV-2 positivity, with an OR of 27.5 (95% CI 2.157–161.9) (Figure 1b, Table 2).
4.377–293.6) (Figure 1d, Table 3). Furthermore, the infected group had a significantly more severe reduction in taste score (−5.8 ± 3.34) when compared to the control group (−2.1 ± 1.86) (P < 0.0001) (Figure 1e). Besides the changes in quantity of smell, four of the 122 participants in the case group (3.27%) and 16 of the 244 participants in the control group (6.5%) reported a strange smell on odorless objects.

### Association between SARS-CoV-2 positivity and various symptoms

A multivariate analysis was performed to identify associations between SARS-CoV-2 infection and various variables, including the presence of respiratory symptoms, appetite loss, nausea, fever, dry cough, productive cough, difficulty breathing, chest congestion, runny nose, sore throat, fatigue, headache, muscle pain, stomachache, diarrhea, dry mouth, hyposmia, anosmia, hypogeusia, ageusia, and asymptomatic. Only four symptoms had a significant positive correlation with SARS-CoV-2 positivity (Table 4). The standardized regression coefficient estimates (β) of anosmia, ageusia, appetite loss, and fever as predictors for SARS-CoV-2 positivity were 0.39, 0.36, 0.13, and 0.10, respectively.

#### Coincidence of taste and smell losses

Most participants in the case group had simultaneous alterations of taste and smell (Figure 2b). Coincidence of taste and smell losses was associated with SARS-CoV-2 positivity (OR 12.28, 95% CI 1.291–4.101, P < 0.01) (Figure 2c).

#### Appetite

A severe change in appetite was associated with SARS-CoV-2 positivity (OR 2.43, 95% CI 1.337–4.384, P < 0.01) (Figure 2d).
Table 4  Multivariate analysis of SARS-CoV-2 infection and various symptoms.

| Parameter estimates | Variable       | Coefficient Estimates | Standard Error | 95% CI (asymptotic) | P value | P value summary |
|---------------------|----------------|----------------------|----------------|---------------------|---------|----------------|
| \( \beta_0 \)       | Intercept      | 0.52                 | 0.06           | 0.3935 to 0.6443    | <0.0001 | ****          |
|                     | With respiratory symptoms | -0.08 | 0.06 | -0.2006 to 0.04555 | 0.215   | ns             |
| \( \beta_2 \)       | Appetite loss  | 0.13                 | 0.06           | 0.01155 to 0.2483   | 0.032   | *             |
| \( \beta_3 \)       | Nausea         | 0.02                 | 0.07           | -0.1217 to 0.1554   | 0.811   | ns             |
| \( \beta_4 \)       | Fever          | 0.10                 | 0.05           | 0.005824 to 0.2001  | 0.038   | *             |
| \( \beta_5 \)       | Dry cough      | 0.00                 | 0.05           | -0.09985 to 0.09708 | 0.978   | ns             |
| \( \beta_6 \)       | Productive cough | -0.10 | 0.06 | -0.2199 to 0.01552 | 0.089   | ns             |
| \( \beta_7 \)       | Difficult breathing | -0.05 | 0.07 | -0.1804 to 0.07624 | 0.425   | ns             |
| \( \beta_8 \)       | Chest congestion | -0.02 | 0.07 | -0.1583 to 0.1223  | 0.801   | ns             |
| \( \beta_9 \)       | Running nose   | -0.02                | 0.06           | -0.1251 to 0.0932   | 0.774   | ns             |
| \( \beta_{10} \)    | Sore throat    | -0.15                | 0.05           | -0.2519 to -0.04922 | 0.004   | **            |
| \( \beta_{11} \)    | Fatigue        | -0.07                | 0.06           | -0.1879 to 0.04695  | 0.239   | ns             |
| \( \beta_{12} \)    | Headache       | -0.11                | 0.05           | 0.0005150           | 0.049   | *             |
| \( \beta_{13} \)    | Muscle pain    | -0.14                | 0.05           | -0.2502 to -0.03556 | 0.009   | **            |
| \( \beta_{14} \)    | Stomachache    | -0.13                | 0.11           | -0.3445 to 0.08299  | 0.230   | ns             |
| \( \beta_{15} \)    | Diarrhea       | -0.03                | 0.07           | -0.1755 to 0.1055   | 0.623   | ns             |
| \( \beta_{16} \)    | Dry mouth      | 0.00                 | 0.07           | -0.1373 to 0.1347   | 0.985   | ns             |
| \( \beta_{17} \)    | No symptoms    | -0.05                | 0.09           | -0.2280 to 0.1306   | 0.593   | ns             |
| \( \beta_{18} \)    | Hypoesthesia   | -0.01                | 0.06           | -0.1196 to 0.1084   | 0.923   | ns             |
| \( \beta_{19} \)    | Anosmia        | 0.39                 | 0.16           | 0.07366 to 0.7102    | 0.016   | *             |
| \( \beta_{20} \)    | Hypogeusia     | 0.00                 | 0.06           | -0.1206 to 0.1147   | 0.961   | ns             |
| \( \beta_{21} \)    | Ageusia        | 0.36                 | 0.16           | 0.03581 to 0.6759    | 0.029   | *             |

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; CI, confidence interval; NS, not statistically significant. Table reports the standardized regression coefficient estimates (\( \beta \)) for the relationship between each symptom and SARS-CoV-2 positivity analyzed by multiple linear regression. Dummy code for outcome (SARS-CoV-2 infection): 0 = negative, 1 = positive. Dummy code for symptoms: 0 = without the symptom, 1 = with the symptom. *P < 0.05, **P < 0.01. Grey highlighted rows indicates symptoms with a significant positive correlation with SARS-CoV-2 positivity. Note: Multiple logistic regression could not be fitted for the data, while multiple linear regression could be fitted well.

Taste preference

There was no difference in preference for bitter, sour, sweet, spicy, salty, and umami taste between the case and control groups (Figure 3a–f). Likewise, no significant correlations were found between any taste preferences and changes in self-reported taste scores (Table 5).

Discussion

Taste and smell losses are emerging symptoms found in COVID-19 patients. However, it is unclear whether these symptoms represent a pathognomonic feature. This matched case–control study found that complete but not partial losses of taste and smell were associated with SARS-CoV-2 positivity. Furthermore, the multivariate analysis of all COVID-19 symptoms suggested that anosmia, ageusia, and appetite loss are the best predictors of SARS-CoV-2 positivity, even better than fever. Consistent with previous studies (La Torre et al., 2020; Carignan et al., 2020), it was found that ageusia and anosmia were strongly associated with SARS-CoV-2 positivity. However, this study is novel in reporting that hypogeusia and hyposmia were not associated with COVID-19. Furthermore, the study findings suggested that coincidence of taste and smell losses along with a severe change in appetite was associated with the infection.

A previous case–control study in Italy reported that ageusia and anosmia were among the symptoms with the highest predictive values for SARS-CoV-2 positivity (La Torre et al., 2020). Likewise, an age-matched case–control study performed in Quebec, Canada also found a strong association between anosmia and ageusia and SARS-CoV-2 positivity (Carignan et al., 2020). Compared to previous studies, the current study was conducted in a larger sample size, with more parameters matched between the groups including age, sex, BMI, and systemic diseases, and more direct data collection instead of an online questionnaire.

The result of no significant association between hypogeusia or hyposmia and SARS-CoV-2 infection was due to the similar incidence of hypogeusia and hyposmia in the control group when compared to the case group. Considering the participants in the control group, the majority of them (75%) had no known systemic diseases (similar to the case group). Interestingly, 80% of participants in the control group had respiratory symptoms as the main reason for getting an RT-PCR test for SARS-CoV-2. Therefore, it is likely that the hypogeusia and hyposmia in the
control group could have resulted from other respiratory diseases. In fact, previous studies have shown that allergic rhinitis, sinusitis, and upper respiratory infections such as influenza or even the common cold can also cause olfactory dysfunction and hyposmia (Risso et al., 2020; Malaty and Malaty, 2013; Seiden and Duncan, 2001). Furthermore, 95% of taste disorders are caused by impairment of smell rather than gustatory loss (Malaty and Malaty, 2013; Soter et al., 2008). Moreover, mild cognitive impairment that occurs sub-clinically could also cause reduced taste and smell senses (Steinbach et al., 2010). Therefore, other respiratory diseases besides COVID-19 and subclinical neurological conditions could have been the causes of hypogeusia and hyposmia in the control group. In contrast, the sudden simultaneous loss of taste and smell in healthy persons is rarely seen in other diseases. Cancer treatment, both chemotherapy and head and neck radiotherapy, can also affect taste and smell (Malaty and Malaty, 2013). Nevertheless, none of the current study subjects in the case and control groups had a history of or was undergoing these treatments. Therefore, we propose that the coincidence of anosmia and ageusia could be a pathognomonic feature of COVID-19, especially in healthy persons with no known systemic diseases. A future large-scale study is warranted to confirm this hypothesis.

A previous study showed that taste thresholds and taste preference were correlated with the onset of radiation-induced taste loss (Vittayakasemsont, 2016). In contrast, the current study showed that taste preference had no association with taste loss in COVID-19 patients. This conflicting result suggests different mechanisms of taste loss by radiation and COVID-19. Previous

Table 5

| Preference  | Spearman rank correlation coefficient (r) | P-value |
|-------------|------------------------------------------|---------|
| Spicy       | -0.017                                   | 0.85    |
| Umami       | 0.0157                                   | 0.83    |
| Salty       | -0.0044                                  | 0.63    |
| Sweet       | 0.018                                    | 0.84    |
| Bitter      | 0.0339                                   | 0.71    |
| Sour        | -0.0005                                  | 0.99    |

The table reports the Spearman rank correlation coefficients for taste preference score (0-6) compared with delta taste score (‘score after’ minus ‘score before’ having symptoms/being exposed to infected persons).

Figure 3. Taste preference and COVID-19. Images a to f: the stacked bars represent the percentage of the total participants in the case and control groups who had a mild (white), moderate (grey), or strong (black) preference for each taste factor as specified in the figures (a–f). P-values derived from the Chi-square test.
studies have suggested that the mechanism of radiation-induced taste loss is from atrophy of the taste buds rather than nerve injury (Just et al., 2005; Deshpande et al. 2018). In contrast, existing evidence suggests that SARS-CoV-2 may use a trans-synaptic pathway to invade from peripheral neurons such as olfactory and gustatory receptors to the central nervous system, i.e. cranial nerve and brain where taste perception occurs (DosSantos et al., 2020). Thus, the virus may be able to completely and aggressively inhibit the gustatory signals regardless of the original taste threshold levels. It is worth noting that the Thai population generally has high taste thresholds when compared to others such as Japanese (Trachootham et al., 2017). Therefore, future studies in other populations with generally low taste thresholds may be worthwhile. Taste and smell losses affect appetite and food intake (Kershaw and Mattes, 2018). This study showed that SARS-CoV-2 infection was associated with more severe appetite loss when compared to the control group. This finding may help explain the malnutrition in COVID-19 patients reported in previous studies (Thibault et al., 2020; Li et al., 2020). Oral hygiene, especially tongue coat, could reduce the sense of taste (Soelmad et al., 2012). Thus, poor oral hygiene can worsen the taste loss in COVID-19 patients.

Our previous study showed that self-tongue brushing could improve both subjective taste perception and reduce the thresholds of sweet, salty, bitter, and sour taste (Madillogovit et al., 2016). Therefore, oral hygiene care, especially tongue brushing, should be recommended to COVID-19 patients.

A recent systematic review and meta-analysis reported that the incidence of olfactory taste disorders in Asians was 18%, which was lower than the incidence in Caucasians (Von Bartheld et al. 2020). In the present study, smell disorders (hyposmia and anosmia) and taste disorders (hypogeusia and ageusia) were observed in 32% and 31% of SARS-CoV-2-infected Thai individuals, respectively. This higher incidence than in general Asian populations could be due to the unique Thai culture. Compared to other Asian food, Thai cuisine is considered spicy and has a stronger taste and smell. Our previous study also showed higher taste thresholds in Thai people compared to Japanese people (Trachootham et al., 2017). Due to the high thresholds, Thai people could be at higher risk of sensory loss than other Asians. Further investigations to explore this assumption would be beneficial.

A strength of this study is the matched case–control design in which every participant was confirmed to be SARS-CoV-2-positive or negative by RT-PCR. Furthermore, blending of the test result at the time of data collection could reduce the subjective bias. The data were collected from participants directly and not by online questionnaire. Nevertheless, a major limitation of this study is that all of the data were self-reported by questionnaire. This was due to a limited access time to the participants. Future studies under better circumstances should include objective measurements of taste, such as filter paper disc or electrogustometry. Changes in appetite may be collected more accurately with diet records of food intake. Previous studies have shown that olfactory taste disorders can appear later than at diagnosis (Spinato et al., 2020; Nakagawara et al., 2020). In this study, the symptoms were evaluated at the time of PCR testing. Thus, the actual prevalence of olfactory taste disorder may be higher. To obtain a more complete picture, future cohort studies with time-course monitoring of taste and smell changes starting from PCR testing until remission are warranted.

In conclusion, the findings of this study suggested that complete but not partial loss of taste and smell were associated with SARS-CoV-2 infection and these could be the best predictors among other symptoms. During the COVID-19 pandemic, healthy persons with sudden simultaneous complete loss of taste and smell should be screened for COVID-19.

Ethics statement

The study protocol was approved on April 30, 2020 by the Ethics Committee of Bamrasnaradur Infectious Diseases Institute (COA. No. IRB/BIDI 023oh/63_ExPD).

Data sharing statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

STROBE statement

The authors have read the STROBE 2007 Statement, and the manuscript was prepared and revised according to the STROBE 2007 checklists.

Conflict of interest

D. Trachootham and A. Lam-Ubol received funding for this research from the Dental Innovation Foundation under Royal Patronage, His Majesty the King’s Dental Service Unit, Thailand. The other authors have no conflicts of interest to declare.

Author contributions

Trachootham D: obtained the grant, study design, data collection, data analysis, writing; Thongyen S: study design, data collection; Lam-Ubol A: obtained the grant, study design, manuscript editing; Chotechung N: study design; Pongpirul W: data collection; Prasithsirikul W: study design and data collection supervision.

Acknowledgements

This research was supported by the Dental Innovation Foundation under Royal Patronage, His Majesty the King’s Dental Service Unit, Thailand. The authors are grateful to Dr Panithee Thammawijaya, Office of Epidemiology, Department of Disease Control, Ministry of Health for scientific input and co-ordination, Mr Worawut Kulkaw and the research staff of the Dental Innovation Foundation under Royal Patronage for administrative support and co-ordination, Dr Nipa Rojrunvasinskul for statistical suggestions, all of the staff at Bamrasnaradur Infectious Diseases Institute for facilitating the data collection, and all participants for their collaboration in the data gathering.

References

Bagheri SH, Asghari A, Farhadi M, Shamshiri AR, Kahir A, Kamrava SK, et al. Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak. Med J Islam Repub Iran 2020;34:62. doi:http://dx.doi.org/10.34171/mjirn.34.62.
Borsett D, Hopkins C, Philips V, Oboholzer R, Tirelli G, Polese J, et al. Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients. Rhinology 2020;58: 104193/ Rhn2191S.
Carignan A, Viallaque I, Grenier C, Berchmans M, Nkgugurutse D, Marcil-Héguy A, et al. Anosmia and dysgeusia associated with SAR-CoV-2 infection: an age-matched case-control study. Can Med Assoc J 2020;192(26):E762–7. doi:http:// dx.doi.org/10.1503/cmaj.200869.
Chamoun E, Liu AAS, Duizer LM, Darlington G, Duncan AM, Haines J, et al. Taste sensitivity and taste preference measures are correlated in healthy young adults. Chem Senses 2019;44(2):129–34. doi:http://dx.doi.org/10.1093/ chemse/bjyz082.
Deshpande TS, Blanchard P, Wang L, Foote RL, Zhang X, Frank SJ. Radiation-related alterations of taste function in patients with head and neck cancer: a systemic review. Curr Treat Options Oncol 2018;19(12):72. doi:http://dx.doi.org/10.1007/ s11864-018-0580-7.
DosSantos MF, Devall S, Aran V, Capra D, Roque NR, et al. Neuromechanisms of SAR-CoV-2: a review. Front Neuroat 2020;14:37. doi:http://dx.doi.org/10.3389/ fnana.2020.00037.
Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome. Rhinology 2020;2020(April). doi: http://dx.doi.org/10.4191/Rhin.2021.1.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. doi: https://doi.org/10.1056/NEJMoa2002032.

Hashmi HAS, Asif HM. Early detection and assessment of COVID-19. Front Med 2020;[June]. doi:http://dx.doi.org/10.3389/fmed.2020.01031.

Jafari M, Seyed Agha M, Sahraai MS. What is the mystery behind anosmia and ageusia in COVID-19? Am J Otolaryngol Head Neck Surg 2020;3(4):1098.

Kang JW, Lee YC, Han K, Kim SW, Lee RH. Epidemiology of anosmia in South Korea: a nationwide population-based study. Sci Rep 2020;10(1):4717. doi: http://dx.doi.org/10.1038/s41598-020-60678-z.

Kershaw J, Mattes RD. Nutrition and taste and smell dysfunction. World J Otorhinolaryngol Head Neck Surg 2018;4(1):3–10.

Just T, Pau HW, Bomhor L, Guthoff RF, Fietkau R, Hummel T. Confocal microscopy of the peripheral gustatory system; comparison between healthy subjects and patients suffering from taste disorders during radiochemotherapy. Laryngoscope 2005;115 (12):1778–82. doi: http://dx.doi.org/10.1097/01.MLG.0000181502.07160.86.

La Torre C, Massetti AP, Guido A, Finamì C, Fantini M, Marte M, et al. Anosmia and ageusia as predictive signs of COVID-19 in health care workers in Italy: a prospective case-control study. J Clin Med 2020;9:2870. doi: https://doi.org/10.3390/jcm9092870.

Li T, Zhang Y, Gong C, Wang J, Liu B, Shi L, et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur J Clin Nutr 2020;. doi: http://dx.doi.org/10.1038/s41430-020-06423-z.

Madillogovit J, Chotechuang N, Trachootham D. Impact of self-tongue brushing on taste perception in Thai older adults: a pilot study. Geriatric Nurs 2016;37 (2):128–36. doi: http://dx.doi.org/10.1016/j.gerinurse.2015.11.004.

Malaty J, Malaty IA. Smell and taste disorders in primary care. Am Fam Phys 2013;88(12):852–9.

Mannama S, Iamsirithaworn S, Uuttayamakul S. Coronavirus disease-19 (COVID-19): J Bamrasnaradura Infect Dis Inst 2020;14(2):124–33.

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China. J Am Med Assoc Neurol 2020;77(6):683–90. doi: http://dx.doi.org/10.1001/jamaneurol.2020.1127.

Nakagawara K, Masaki K, Uwamino Y, Kabata H, Uchida S, Uno S, et al. Acute onset olfactory/taste disorders are associated with a high viral burden in mild or asymptomatic SARS-CoV-2 infections. Int J Infect Dis 2020;99:19–22. doi: http://dx.doi.org/10.1016/j.ijid.2020.07.034.

Risso D, Drayna D, Morini G. Alteration, reduction and taste loss: main causes and potential implications on dietary habits. Nutrients 2020;12:3284. doi: http://dx.doi.org/10.3390/nu12113284.

Seiden AM, Duncan HJ. The diagnosis of a conductive olfactory loss. Laryngoscope 2001;111(1):9–14.

Solemdal K, Sandvik L, Williamsen T, Mowe M, Hummel T. The impact of oral health on taste ability in acutely hospitalized elderly. PLoS One 2012;7(5):e36557. doi: http://dx.doi.org/10.1371/journal.pone.0036557.

Soter A, Kim J, Jackman A, Tourbier I, Kaul A, Doty RL. Accuracy of self-report in detecting taste dysfunction. Laryngoscope 2008;118(4):611–7.

Spinato G, Fabbris C, Polese J, et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. J Am Med Assoc 2020;323:2089–90.

Steinbach S, Hundt W, Vaitl A, et al. Taste in mild cognitive impairment and Alzheimer’s disease. J Neurol 2010;257(2):238–46.

Sunnak W, Huang N, Bécavin C, Berg M. Network HLB. SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways. ArXiv 2020. arXiv: 2003.06122v1.

Tanasa IA, Manciuc C, Carauceleau N, Navolani Di, Bohiltea RE, Nemescu D. Anosmia and ageusia associated with coronavirus infection (COVID-19) – what is known?. Exp Th Med 2020;20:2344–7.

Thibault R, Coëffier M, Joly F, Bohé, Schneider SM, Déchelette F. How the COVID-19 epidemic is challenging our practice in clinical nutrition-feed-back from the field. Eur J Clin Nutr 2020;.. doi: http://dx.doi.org/10.1038/s41430-020-00757-6.

Trachootham D, Satoh-Kuwada S, Lam-Ubol A, Promkam C, Chotechuang N, Sasano T, et al. Differences in taste perception and spicy preferences: a Thai-Japanese cross-cultural study. Chem Senses 2017;43(1):65–74. doi: http://dx.doi.org/10.1093/chemse/bju071.

Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope 2020;2020(April). doi: http://dx.doi.org/10.1002/lary.28892.

Vittayakasemsont K. The association between pre-treatment dietary behavior and taste alteration in Thai head and neck cancer patients who underwent definitive radiotherapy. (Master Thesis). Mahidol University; 2016.

Vittayakasemsont K, Klantong C, Phukosi K, Chavasit V, Sinthusek T, Trachootham D. Association between pretreatment dietary preference and weight loss after radiation therapy in head and neck cancer patients: a pilot study. Nutr Cancer 2019;71(2):230–9. doi: http://dx.doi.org/10.1080/01635581.2019.1578393.

von Bartheld CS, Hagen C, Nilsson J, et al. Prevalence of chemosensory dysfunction in COVID-19 patients: a systematic review and meta analysis reveals significant ethnic differences. ACS Chem Neurosci 2020;11:2944–61.

World Health Organization. Coronavirus disease (COVID-19) Situation report (2020a) https://www.who.int/publications/m/item/weekly-epidemiological-update–23–february–2021 Updated on 23 February 2021 [accessed on 23 April 2021].

World Health Organization. WHO Characterizes COVID-19 as Pandemic–11 March 2020 (2020b). Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen [Accessed 30 December 2020].